ARID1A及PIK3CA在膀胱尿路上皮癌中的表达及临床病理意义

王晨静; 李超; 咸娴; 王胜; 何雷; 范多娇

doi:10.13201/j.issn.1001-1420.2021.06.001

ARID1A及PIK3CA在膀胱尿路上皮癌中的表达及临床病理意义

- 1. 保定市第二医院病理科河北保定, 071051);
- 2. 定州市人民医院病理科;
- 3. 保定市第二医院泌尿外科;
- 4. 徐水区人民医院普外肿瘤科;
- 5. 保定市第二医院科教科
基金项目:
保定市科学技术研究与发展计划项目(No:2041ZF021)

详细信息

通讯作者: 王晨静,E-mail:496437376@qq.com

中图分类号: R737.11

收稿日期: 2020-10-22

Expression and significance of ARID1A and PIK3CA in bladder urothelial carcinoma

- 1. Department of Pathology, Baoding Second Hospital, Baoding, Hebei, 071051, China;
- 2. Department of Pathology, Dingzhou People's Hospital;
- 3. Department of Urology, Baoding Second Hospital;
- 4. General Surgery and Oncology Department, Xushui District People's Hospital;
- 5. Department of Science and Education, Baoding Second Hospital

More Information

Corresponding author: WANG Chenjing, E-mail: 496437376@qq.com

Received Date: 22 October 2020

摘要

摘要: 目的:探讨膀胱尿路上皮癌(BUC)组织中ARID1A及PIK3CA的表达及意义。方法:采用免疫组化EnVision法检测107例膀胱尿路上皮癌(BUC组)及28例癌旁组织(癌旁组)中ARID1A、PIK3CA及Ki-67的表达水平,并将BUC组按照临床病理特征进行分组,统计分析ARID1A、PIK3CA在各组间表达的差异及相关性。结果:ARID1A在BUC组中有42.06%呈缺失表达,而在癌旁组中仅7.14%呈缺失表达,二者差异有统计学意义(P<0.05)。PIK3CA在BUC组中有74例(69.16%)表达显著增强,而在癌旁组中仅7例(25%)呈强阳性表达,两组间比较差异有统计学意义(P<0.05)。结合患者的临床病理特征进行分析,发现ARID1A的缺失表达与肿瘤的浸润深度、分级及Ki-67增殖指数有关(P<0.05),PIK3CA的阳性表达与肿瘤的浸润深度有关(P<0.05),与分级、Ki-67增殖指数无关(P>0.05)。相关性分析结果显示ARID1A与PIK3CA之间的表达无明确相关性(r=-0.062,P>0.05),复发与否与年龄、病变级别、浸润深度、PIK3CA蛋白阳性表达率呈正相关。结论:ARID1A及PIK3CA在BUC患者癌组织中的表达明显增强,且与病变级别、肿瘤浸润密切相关,但两种蛋白间并无相关性,二者可能通过不同的途径参与BUC的发生、进展。并且PIK3CA蛋白阳性表达可明显增加BUC的复发率,进一步为探究BUC提供了新的思路。
- 膀胱肿瘤 /
- 尿路上皮癌 /
- AT丰富结合域1A /
- 磷脂酰肌醇3-激酶催化亚基 /
- 免疫组织化学
Abstract: Objective: To investigate the expression and significance of ARID1 A and PIK3 CA in bladder urothelial carcinoma(BUC).Methods: Immunohistochemical methods were employed to evaluate protein level of ARID1 A and PIK3 CA in 107 cases of BUC and 28 cases of adjacent tissues. The BUC tissues were grouped by clinical and pathological features, and the difference and relations of ARID1 A and PIK3 CA in each group were analyzed.Results: The loss rate of ARID1 A was 42.06% in BUC, but only 7.14% in adjacent tissues. The positive rate of PIK3 CA in BUC(69.16%) was significantly higher than that in adjacent tissues(25%)(P<0.05). The clinical features of 107 cases of BUC were retrospectively analyzed, which showed that the expression of ARID1 A was significantly associated with histopathology grading, depth of invasion and Ki-67 index. The expression of PIK3 CA was significantly associated with depth of invasion, but not related to age, sexuality, recurrence or Ki-67 index(P>0.05). The results of correlation analysis showed that there was no clear correlation between ARID1 A and PIK3 CA(r=-0.062, P>0.05). The recurrence was positively correlated with age, histopathology grading, depth of invasion and PIK3 CA.Conclusion: ARID1 A and PIK3 CA play an important role in the development and progression of BUC through different pathways. The expression of PIK3 CA maybe increase the recurrence of BUC. It will provide a new idea for exploring the prevention and treatment of urothelial carcinoma of the bladder.
- bladder tumor /
- urothelial carcinoma /
- the AT-rich interactivedomain 1A /
- phosphoinositide 3 kinase catalytic alpha polypeptide /
- immunohistochemistry

HTML全文

参考文献(17)

[1]	Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
[2]	Kim PH,Cha EK,Sfakianos JP,etal.Genomic Predictors of Survival in Patients with High-Grade Urothelial Carcinoma of the Bladder[J].Eur Urol,2015,67(2):198-201.
[3]	Ibarrola-Villava M,Llorca-Cardeňosa MJ,Tarazona N,et al.Deregulation of ARID1A,CDH1,cMET and PIK3CA and target-related microRNA expression in gastric cancer[J].Oncotarget,2015,6(29):26935-26945.
[4]	章萍萍,黄文斌,王晓蕾,等.膀胱尿路上皮癌中碳酸酐酶IX的表达及意义[J].临床与实验病理学杂志,2018,34(3):317-318.
[5]	姜家利,夏玉军.甲状腺癌组织中Pl3Kp85α、EZRlN和ARlD1A表达检测及作用探讨[J].医学检验与临床,2019,30(2):5-9.
[6]	Dugas SG,Müller DC,Magnen CL,etal.Immunocytochemistry for ARID1A as a Potential biomarker in Urine Cytology of Bladder Cancer[J].Cancer Cytopathol,2019,127(9),578-585.
[7]	Cao Q,Wang C,Ding Y,et al.ARID1A upregulation predicts better survival in patients with urothelial bladder carcinoma[J].J Int Med Res,2020,48(4):300060519895687.
[8]	Balbás-Martínez C,Rodríguez-Pinilla M,Casanova A,et al.ARID1A alterations are associated with FGFR3-Wild type,Poor-Prognosis,Urothelial Bladder Tumors[J].PLoS One,2013,8(5):e62483.
[9]	张倩,颜海波,刘锋.ARID1A对乳腺癌生长的抑制及潜在调控机制[J].复旦学报(医学版),2015,42(4):427-434.
[10]	钟键,金正贤,卞卫星,等.FGFR3和PIK3CA基因突变影响膀胱癌的预后[J].中国癌症杂志,2019,29(11):880-886.
[11]	王忠禹.PIK3CA促进膀胱癌生长,侵袭和转移的机制研究[D].武汉:华中科技大学,2018.
[12]	Rodriguez Pena MDC,Tregnago AC,Eich ML,et al.Spectrum of Genetic Mutations in De Novo PUNLMP of the Urinary Bladder[J].Virchows Arch,2017,471(6):761-767.
[13]	Ousati Ashtiani Z,Mehrsai AR,Pourmand MR,et al.High Resolution Melting Analysis for Rapid Detection of PIK3CA Gene Mutations in Bladder Cancer:A Mutated Target for Cancer Therapy[J].Urol J,2018,15(1):26-31.
[14]	Wiegand KC,Hennessy BT,Leung S,et al.A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation a Nalysis:protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation[J].BMC Cancer,2014,14:120.
[15]	Zeng Y,Liu Z,Yang J,et al.ARID1A is a tumour suppressor and inhibits glioma cell proliferation via the PI3K pathway[J].Head Neck Oncol,2013,5(1):6.
[16]	Takeda T,Banno K,Okawa R,et al.ARID1A gene mutation in ovarian and endometrial cancers(Review)[J].Oncol Rep,2016,35(2):607-13.
[17]	戴维,梁朝朝,张力,等.TPD52 L1(D53)蛋白在膀胱尿路上皮癌中的表达和预后[J].安徽医科大学学报,2019,54(4):635-639.